Results 121 to 130 of about 67,096 (237)

Molecular pathology of phyllodes tumours of the breast—much more than MED12

Histopathology, EarlyView.
Phyllodes tumours can develop from fibroadenomas bearing MED12 variants by the development of pTERT alterations (“MED12 pathway”) or de novo (“MED12 independent pathway”). Grade progression is associated with increasing genetic complexity including cancer driver gene aberrations. Molecular alterations can be useful in assigning grade and distinguishing
Jia‐Min B Pang, Kylie L Gorringe, Puay Hoon Tan, Stephen B Fox   +3 more
wiley   +1 more source

Neurofibromatosis Type 1: Optimizing Management with a Multidisciplinary Approach

Journal of Multidisciplinary Healthcare
Shaan Lalvani, Rebecca M Brown Department of Neurology, The Mount Sinai Hospital, New York, NY, USACorrespondence: Rebecca M Brown, MD, PhD, The Mount Sinai Hospital, Department of Neurology, 1216 5th Avenue, New York, NY, 10029, USA, Tel +1 2128248579 ...
Lalvani S, Brown RM
doaj  

The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma

Cell Reports
Summary: Hotspot BRAF, hotspot NRAS, and NF1 loss-of-function mutations are found in approximately 50%, 25%, and 15% of cutaneous melanomas, respectively. Compared to mutant BRAF and NRAS, the role of NF1 loss in melanoma remains understudied.
Diana Berry, Dan Moldoveanu, Shivshankari Rajkumar, Mathieu Lajoie, Tiffany Lin, Daméhan Tchelougou, Samridhi Sakthivel, Itai Sharon, Antoine Bernard, Sandy Pelletier, Yael Ripstein, Alan Spatz, Wilson H. Miller, Rahima Jamal, Réjean Lapointe, Anne-Marie Mes-Masson, Kevin Petrecca, Ari-Nareg Meguerditchian, Keith Richardson, Beatrice Wang, May Chergui, Marie-Christine Guiot, Kevin Watters, John Stagg, T. Martin Schmeing, Francis Rodier, Simon Turcotte, Catalin Mihalcioiu, Sarkis Meterissian, Ian R. Watson   +29 more
doaj   +1 more source

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Journal of the European Academy of Dermatology and Venereology, EarlyView.
When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo, Romain Levard, Julie Cassecuel, Amir Khammari, Gaelle Quereux, Florent Grange, Henri Montaudié, Florence Brunet‐Possenti, Justine Lavaud, Marie‐Thérèse Leccia, Géraldine Jeudy, Anne Dompmartin, Brigitte Dreno, Jean‐Matthieu L’Orphelin   +13 more
wiley   +1 more source

International Dermoscopy Society consensus recommendations for the management of lentigo maligna

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Lentigo maligna (LM) poses diagnostic and therapeutic challenges amid rising incidence and limited high‐quality evidence. This international expert consensus provides pragmatic, evidence‐based and expertise‐informed guidance on LM diagnosis and management.
Ana‐Maria Forsea, Riccardo Pampena, Bengu Nisa Akay, Zoe Apalla, Giuseppe Argenziano, Giulia Briatico, Ralph Braun, Horacio Cabo, Raul Cabrera, Cristina Carrera, Elisa Cinotti, Claudio Conforti, Enzo Errichetti, Gerardo Ferrara, Roberta Giuffrida, Stefania Guida, Pascale Guitera, Allan C. Halpern, Stephen Heyes, Rainer Hofmann‐Wellenhof, Angela M. Hong, Natalia Jaimes, Raimonds Karls, Harald Kittler, Teresa Kränke, Konstantinos Liopyris, Jie Liu, Caterina Longo, Josep Malvehy, Ashfaq A. Marghoob, Hoda Moneib, David Moreno Ramirez, Elvira Moscarella, Eduardo Nagore, Cristian Navarrete‐Dechent, John Paoli, Giovanni Pellacani, Ketty Peris, Susana Puig, Cliff Rosendahl, Lidia Rudnicka, Ahmed Sadek, Philippe Saiag, Gabriel Salerni, Alon Scope, Hans Peter Soyer, Michela V. Starace, Wilhelm Stolz, David L. Swanson, Luc Thomas, Philipp Tschandl, Iris Zalaudek, Aimilios Lallas   +52 more
wiley   +1 more source

Endoscopic Ultrasound for the Management of Pancreatic Neuroendocrine Tumors: Diagnosis, Treatment, and Future Perspectives

Journal of Gastroenterology and Hepatology, EarlyView.
ABSTRACT Pancreatic neuroendocrine tumors (PanNETs) are increasingly diagnosed, reflecting greater clinical awareness, improved imaging, and revised classification. This review summarizes evidence on epidemiology, diagnostic workup, and endoscopic ultrasound (EUS)–guided management of PanNETs, encompassing diagnostic evaluation, tissue acquisition, and
Angelo Bruni, David Meacci, Roberto Falbo, Marco Fichera, Francesco Poggioli, Riccardo Casadei, Claudio Ricci, Leonardo Henry Eusebi   +7 more
wiley   +1 more source

Values of Individuals With Rare Genetic Neurodevelopmental Disorders and Their Family/Caregivers in Healthcare: A Scoping Review to Inform Guideline Development

Journal of Intellectual Disability Research, EarlyView.
ABSTRACT Background Healthcare decision‐making for individuals with rare genetic neurodevelopmental disorders (RGNDs) associated with intellectual disabilities (ID) can be complex due to the intersection of lifelong care needs, limited medical expertise and communication barriers.
Mirthe J. Klein Haneveld, Louise Cox, Petri J. C. M. Embregts, Alistair R. Niemeijer, Martina C. Cornel, Charlotte M. W. Gaasterland, Agnies M. van Eeghen   +6 more
wiley   +1 more source

Quality of Life in Children with Neurofibromatosis Type 1: Agreement between Parents and Patients, and the Role of Disease Severity and Visibility

Children
Background: Neurofibromatosis type 1 (NF1) is a genetic disorder that affects multiple systems in the body, often leading to physical disfigurements and a wide range of clinical symptoms.
Nicola Davide Cavallo, Paola Maietta, Silverio Perrotta, Pasquale Moretta, Marco Carotenuto, Maria Esposito, Gabriella Santangelo, Claudia Santoro   +7 more
doaj   +1 more source

Who can safely discontinue lifelong follow‐up among patients with sporadic pheochromocytoma and paraganglioma?

Journal of Internal Medicine, EarlyView.
Background Current guidelines recommend at least 10 years of follow‐up for all pheochromocytoma and paraganglioma (PPGL) patients and lifelong monitoring for high‐risk individuals. Nonetheless, data identifying patients who may not require routine lifelong follow‐up are scarce.
Min Jeong Park, Seung Shin Park, Won Woong Kim, Su‐Jin Kim, Yu‐Mi Lee, Kyu Eun Lee, Tae‐Yon Sung, Jae‐Kyung Won, Dong Eun Song, Jung‐Min Koh, Sara Talvacchio, Tamara Prodanov, Hussam Alkaissi, Karel Pacak, Seung Hun Lee, Jung Hee Kim   +15 more
wiley   +1 more source

Conditional survival in glioblastoma: The evolution of prognostic factors over time

International Journal of Cancer, Volume 158, Issue 10, Page 2571-2580, 15 May 2026.
What's New? Neurooncologists rely on glioblastoma risk stratification systems for incorporating known disease‐ and patient‐specific factors at diagnosis. Although useful for general comparison and disease monitoring, these estimates are less informative for patients who survive beyond various time intervals post‐diagnosis.
Timothy Mueller, Flavio Vasella, Julia Velz, Stefanos Voglis, Kevin Akeret, Luis Padevit, Morton Schubert, Jonathan Weller, Sarah Brüningk, Elisabeth Rushing, Johannes Sarnthein, Dorothee Gramatzki, Levin Häni, Andreas Raabe, Anna M. Zeitlberger, Oliver Bozinov, Emilie Le Rhun, Michael Weller, Luca Regli, Marian C. Neidert   +19 more
wiley   +1 more source